Premium
Evaluation of Phenolic Glycolipid‐I (PGL‐I) Antibody as a Multidrug Therapy (MDT) Monitor
Author(s) -
Prakash Kunti,
Sehgal Virendra N.,
Aggarwal Ravindra
Publication year - 1993
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1993.tb03822.x
Subject(s) - leprosy , mycobacterium leprae , serology , glycolipid , antibody , antibody titer , immunology , antigen , medicine , titer
Since phenolic glycolipid‐I (PGL‐I) is an unequivocal marker for Mycobacterium leprae , this antigen has been a good candidate for the serodiagnosis and monitoring of the effectiveness of leprosy chemotherapy. The present study, a continuation of an earlier report, was undertaken to estimate PGL‐I antibody titers in 40 leprosy patients 3 and 6 months after starting MDT. All the leprosy groups showed significant declines in anti PGL‐I reactivity after 6 months. There was a good correlation between bacteriological indices (BI) and anti PGL‐I antibody levels. Thus, PGL‐I based serology may be useful in monitoring the response to multidrug therapy.